Group "Proteomics and Cancer Cell Signaling"

The overarching goal of our work is to understand cancer at the proteomic level and to thus inform and develop new strategies for treatment. Our research group consists of physician scientists, geneticists and investigators with a strong background and track-record in high-sensitivity & high-throughput mass-spectrometry (MS) technology platforms and in implementing analytical pipelines (bioinformatics, multiomics data integration). 

We are interested in studying the mechanisms of cancer development and progression utilizing cutting-edge mass spectrometry (MS) technology and systems biology approaches. We aim to study how these mechanisms determine clinical phenotype and response to cancer therapy.

We like to perform ambitious research projects in a collaborative, fun, and team-oriented environment. We have formed a strong network of clinical and research collaborations in Germany and internationally to pursue innovative studies.

We welcome applications for master, graduate, and post-doctoral positions. For post-doc we also encourage applications for external fellowships. We seek highly ambitious and motivated candidates who share our commitments to science and passion for interdisciplinary research in MS-technology, medicine, cancer biology, and systems biology or similar. Interested candidates are welcome to reach out to our group leader.

  • Insights into the proteome of therapy resistant pediatric acute lymphoblastic leukemia
  • Exploring the osteosarcoma pathophysiology in an orthotopic mouse model
  • Development of MS sample preparation methods
  • Single cell proteome technology
  • Characterizing oncokinase persistent signaling architecture
  • Proteome landscape of acute myeloid leukemia
  • JAK2 signaling in myeloproliferative neoplasms
  • Regulation of splicing factors in cancer


Our lab is experienced in the following technology:

High-throughput proteomics, phosphoproteomic, phospho-tyrosine profiling, ubiquitinome, and profiling other post-translational modifications, plasma and cellular secretome profiling, HLA peptidomics, RNA-interactome and other MS based analyses.




  • Dr. Ashok Kumar Jayavelu (Group leader)
  • Nicole Dickemann (Technical Assistant)
  • Noelle Jung (TA trainee)
  • Joris Maximilian Frenz (PhD student)
  • Lianghao Mao (MD student)
  • Yongjie Wang (Guest PhD student)
  • Dr. Lavanya Mokada Gopal (Post-Doctoral Researcher)
  • Thorben Hennig (Master student)
  • Marlene Adams (Bachelor student)

Ashok Kumar Jayavelu

Group Leader Proteomics and Cancer Cell Signaling

Postal address:


KiTZ - Hopp Children's Cancer Center Heidelberg
Im Neuenheimer Feld 350
D- 69120 Heidelberg


1.    Jayavelu AK *, Wolf S*, Buettner F *, Alexe G , Häupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann D, Wagner S, Donato E, Andresen C, Wilke A, Zindel A, Splettstoesser B, Plessmann U, Münch S, Elardat KA, Makowka P, Acker F, Enssle J, Cremer A , Schnuetgen F, Kurrle N, Chapuy B, Löber J, Hartmann S, Wild P, Wittig I, Huebschmann D, Kaderali L, Cox J, Brüne B, Röllig C, Thiede C, Steffen B, Bornhäuser M, Trumpp A, Urlaub H, Stegmaier K, Serve H#, Mann M# and Oellerich T#. The Proteogenomic Subtypes of Acute Myeloid Leukemia. Cancer Cell. 2022 Feb 28:S1535-6108(22)00058-7

2.    Schnoeder TM, Schwarzer A, Jayavelu AK, Hsu CJ, Kirkpatrick J, Döhner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, Dolnik A, Assi SA, Nafria M, Jiang L, Dai YT, Chen Z, Chen SJ, Kellaway SG, Ptasinska A, Ng ES, Stanley EG, Elefanty AG, Buschbeck M, Bierhoff H, Brodt S, Matziolis G, Fischer KD, Hochhaus A, Chen CW, Heidenreich O, Mann M, Lane SW, Bullinger L, Ori A, Eyss BV, Bonifer C, Heidel F. Blood. 2021 Oct 25:blood.2021012778.

3.    Haider N*, Lebastchi J*, Jayavelu AK*, Batista TM, Pan H, Dreyfuss JM, Carcamo-Orive I, Knowles JW, Mann M, Kahn CR. Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex. J Clin Invest. 2021. Nov 1;131(21) PMID: 34506305 * shared first-authors.

4.    Perner F, Schnoeder TM , Xiong  Y, Jayavelu AK, Mashamba N , Santamaria NT, Huber N, Todorova K, Hatton C , Perner B, Eifert T, Murphy C, Hartmann M, Hoell JI, Schröder N, Brandt S, Hochhaus A, Mertens PR, Mann M, Armstrong SA , Mandinova A, Heidei FH. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia 2021, Aug31. PMID: 34465866 DOI: 10.1038/s41375-021-01393-0.

5.    Jayavelu AK,  Schnöder TM, Perner F,  Herzog C,  Meiler A, Krishnamoorty G, Mohr J, , Kathner C, Stephan BE, Austin R, Brandt S, Palandri F, Odenwald K, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M* and Heidel FH*. Splicing factor Ybx1 maintains persistent Jak2-mutated neoplasms. Nature. 2020 Dec;588(7836):157-163.

6.    Batista TM,  Jayavelu AK, Albrechtsen NJW,  Iovino S, Lebastchi J,  Pan H, Dreyfuss J, Krook A,  Zierath RJ, Mann M, Kahn RC. A Cell-Autonomous Signature of Dysregulated Protein Phosphorylation Underlies Muscle Insulin Resistance in Type 2 Diabetes. Cell Metabolism. 2020 Nov 3;32(5):844-859.

7.    Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schörder K, Shah AM, Scholl S, Frey S, Fisher T, Heidel HF and Böhmer FD. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3-ITD positive AML cells. Leukemia, 2016 Feb;30(2):473-83.